Cannabis Therapeutic Potential Hinges on Personalized Dosing and ECS Interaction
TL;DR
- Cannabis use can mitigate anxiety and panic attacks at low doses, but high THC levels can induce or worsen these conditions, underscoring the critical importance of precise dosing for therapeutic benefit.
- The endocannabinoid system (ECS) acts as the body's master regulator, maintaining homeostasis by interacting with various bodily systems, making cannabis effective for a wide range of conditions.
- While cannabis is not federally legal, over 30 states have legalized it, yet pharmaceutical and other industries may lobby to maintain its Schedule I status due to potential profit disruption.
- Cannabis's therapeutic benefits are strongest for seizures, chronic pain, and appetite stimulation, supported by pharmaceutical applications like Epidiolex and Marinol, though research varies for other conditions.
- Adolescents face unique risks from cannabis, particularly high-THC vape carts, which can alter brain development and potentially lower the age of schizophrenia onset in genetically predisposed individuals.
- Smoking cannabis is less carcinogenic than tobacco, but dry herb vaporization offers a healthier inhalation method by selectively vaporizing compounds without combustion byproducts.
- For individuals sensitive to THC, CBD-dominant hemp flower or low-THC products, combined with careful titration, can offer therapeutic benefits while minimizing psychoactive side effects.
Deep Dive
Dr. Riley Kirk, a cannabis research scientist, argues that cannabis, when used mindfully, offers significant therapeutic potential by interacting with the body's endocannabinoid system (ECS). This system's role in regulating sleep, mood, and appetite means cannabis can address a wide range of conditions, from chronic pain and seizures to menopausal symptoms and anxiety. However, the effectiveness and safety of cannabis are highly individualized, depending on dose, consumption method, and personal genetics, necessitating a personalized approach rather than a one-size-fits-all pharmaceutical model.
The nuanced relationship between cannabis and well-being is complicated by historical stigma and the plant's complexity. While cannabis does not activate the same addiction pathways as harder drugs, dependency can occur, though it is comparable to daily reliance on caffeine or SSRIs, provided it does not cause adverse consequences. For adolescents, risks are amplified by the developing brain's sensitivity and the potency of modern cannabis products, particularly high-THC vape carts, which differ significantly from the weaker strains common in earlier decades. Inhalation, especially via dry-herb vaporizers, is generally considered safer for lung health than smoking, as it avoids combustion byproducts. Edibles offer an alternative but are ineffective for a portion of the population due to genetic variations in processing.
The historical path of cannabis reveals a journey from ancient medicinal use to its demonization through propaganda rooted in racism, leading to its Schedule I classification. Despite this, scientific understanding has advanced, identifying the ECS and its receptors, paving the way for pharmaceutical applications like Epidiolex and Marinol. The continued federal prohibition in the U.S. creates a fragmented legal landscape, where state-level legalization coexists with ongoing criminalization, particularly impacting minority communities, and where the industry is influenced by lobbying from established pharmaceutical, tobacco, and alcohol companies that perceive cannabis as a competitive threat.
The second-order implications of this scientific and cultural evolution are profound. For individuals, it means a paradigm shift from viewing cannabis solely as an illicit recreational substance to recognizing its potential as a personalized medicine, requiring education and self-experimentation to optimize its benefits. For society, it highlights the urgent need to address the lingering effects of cannabis prohibition, including the disproportionate incarceration of minority groups, and to reconcile federal law with increasing state-level legalization and scientific evidence. The future of cannabis use hinges on navigating this complex interplay of individual response, scientific discovery, and evolving societal and legal frameworks, emphasizing informed, responsible, and personalized application.
Action Items
- Audit endocannabinoid system (ECS) function: Identify 3-5 personal regulatory pathways (sleep, mood, appetite) to understand cannabis interaction.
- Measure THC sensitivity: Track anxiety levels across 3-5 different THC doses to establish personal tolerance thresholds.
- Evaluate CBD efficacy for anxiety: Use 200mg+ CBD doses for 2 weeks to assess impact on anxiety symptoms.
- Profile 3-5 cannabis strains: Document effects (uplifted, mellow, creative) and THC/CBD ratios to curate personalized experiences.
- Assess dry herb vaping for lung health: Compare lung capacity and phlegm production over 1-month period using dry herb vape vs. smoking.
Key Quotes
"The endocannabinoid system -- and how it works in the body. The endocannabinoid system is an endogenous, meaning inside our body, system that produces cannabinoids. These cannabinoids act on our cannabinoid receptors in our body and then they cause a ton of different things to happen. Some of the best known reasons that the endocannabinoid system is occurring in our body is to help us regulate things like sleep, like appetite, like mood."
Dr. Riley Kirk explains that the endocannabinoid system (ECS) is a natural bodily system that produces cannabinoids. These compounds interact with receptors in the body to regulate essential functions such as sleep, appetite, and mood. Dr. Kirk emphasizes that everyone possesses this system, regardless of cannabis use, and its primary role is to maintain internal balance.
"THC gets you high. That is the compound that gets you high and that is really what dominates the legal cannabis industry is THC products that are going to be used for either medicine or for adult use purposes, recreational purposes. Then you have CBD. CBD does not get you high, but it has a ton of medicinal potential."
Dr. Riley Kirk differentiates between THC and CBD, two primary compounds in cannabis. She clarifies that THC is the psychoactive component responsible for the "high" and is the focus of much of the legal industry. In contrast, CBD is non-psychoactive but possesses significant medicinal properties, such as anxiety reduction and anti-inflammatory effects.
"The term marijuana like I use it because a lot of people that's how they refer to THC dominant cannabis, but that term I know a lot of people have problems with because it's rooted in a lot of racism. That's how we got to marijuana the term because it was essentially used to target Mexican Americans."
Dr. Riley Kirk addresses the historical context and problematic origins of the term "marijuana." She explains that the term was deliberately used in propaganda campaigns to associate cannabis use with Mexican Americans, contributing to its criminalization and stigmatization. Dr. Kirk suggests using "cannabis" as a more neutral and accurate term.
"The difference is -- if we were to go way back in time to when cannabis was first being cultivated, your sativa type varieties were your really tall varieties that had very stringy leaves kind of. And they were grown in different places. Then your indica type varieties, which were short and stout and had really fat leaves. And they're both kind of known for producing different effects in people."
Dr. Riley Kirk describes the historical distinction between sativa and indica cannabis varieties. She notes that sativa types were typically tall with stringy leaves, while indica types were short and stout with broad leaves. These classifications were historically associated with different effects, with sativas often linked to uplifting and energetic experiences, and indicas to more mellow, relaxing effects.
"The data that we know about THC and driving is that people who are naive to cannabis, new users, it is not safe to drive. It messes up their hand eye coordination, their motor control quite substantially. However, people who have a tolerance to cannabis, people who have been consuming for a long time, there was really statistically not a danger to the road."
Dr. Riley Kirk discusses the impact of THC consumption on driving ability. She states that new users, or those naive to cannabis, experience significant impairment in hand-eye coordination and motor control, making driving unsafe. However, individuals with a developed tolerance to THC show statistically no increased danger when driving, suggesting their bodies have adapted to its effects.
"The biggest concern with the younger generation is I don't know what to expect when people are consuming vape carts this young, whereas if they're consuming really really low dose cannabis products like what we consumed, you're going to get high but it's not going to be like you're overwhelming your brain with THC."
Dr. Riley Kirk expresses concern regarding the risks of cannabis use among adolescents, particularly with modern high-THC vape cartridges. She contrasts this with the lower-THC products available when she and the interviewer were younger, suggesting that current high-potency products may overwhelm a developing brain more significantly. Dr. Kirk highlights the ease of discreet use with vape carts as another factor contributing to this concern.
Resources
External Resources
Books
- Reefer Wellness: Understanding Cannabis Science, Culture, and Medicines by Dr. Riley Kirk - Mentioned as the guest's new book.
Articles & Papers
- "The Science of Cannabis: Does It Help or Hurt With Anxiety? Is It Addictive? What's the Safest Way To Use It?" (10% Happier with Dan Harris) - This is the title of the podcast episode featuring Dr. Riley Kirk.
People
- Dr. Riley Kirk - Guest, cannabis research scientist and educator with a Ph.D. in pharmaceutical sciences.
- Dan Harris - Host of the podcast.
- Jeff Warren - Friend and meditation teacher who guided a custom meditation for the episode.
- Dr. Raphael Mechoulam - Mentioned as a prominent cannabis scientist who discovered THC.
- Dr. Allen Hawley - Mentioned as the discoverer of cannabinoid receptors in the United States.
Organizations & Institutions
- 10% Happier with Dan Harris - The podcast where this episode aired.
- The Network of Applied Pharmacognosy (NAP) - A nonprofit organization co-founded by Dr. Kirk that conducts research.
Podcasts & Audio
- Bioactive podcast - Dr. Riley Kirk's podcast discussing cannabis and other natural products.
Other Resources
- Endocannabinoid system (ECS) - Discussed as the body's internal system that cannabis interacts with.
- Homegrown cannabis - Recommended as a safe and balanced source for cannabis products.
- Reefer Madness - The movie that inspired the title of Dr. Riley Kirk's book.
- Last Prisoner Project - A nonprofit organization dedicated to advocating for the release of individuals incarcerated for cannabis-related charges.